One Biosciences, a techbio company involved in single-cell tumor transcriptomic profiling, has scored $17.5 million (€15 million) in Series A funding.
Transcriptomics is the study of the transcriptome, a set of total RNAs present in a cell including mRNA, rRNA, tRNA and other noncoding RNAs.
The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures.
The round brings One Biosciences' total funding to more than $23.4 million (€20 million), including seed financing from Home Biosciences, a venture capital company that focuses on biotech companies.
WHAT IT DOES
One Biosciences' technology creates profiles of patient tumors to help accelerate the development of precision medicine.
The company extracts high-quality single-cell data from formalin-fixed paraffin-embedded (FFPE) and frozen routine biopsy samples.
Its proprietary AI platform then automatically generates single-cell reports with a two-week turnaround time, delivering "actionable insights" via functional signatures to help guide treatment decisions, patient selection and therapy development, and optimize clinical trials.
One Biosciences' platform, OneMap, is a clinical diagnostic platform that connects single-cell analysis and AI to provide clinicians with tumor information from routine tumor biopsy specimens, which the company says allows for data-driven therapeutic decisions within two weeks.
The company's OneCure is an integrated platform for pharmaceutical and biotech partners that leverages single-cell tumor profiling to "identify predictive biomarkers and guide patient selection in clinical trials."
The funds will be used to accelerate the clinical development of OneMap and strengthen partnerships with pharma and biotech firms.
"This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care and accelerate drug development," Hedi Ben Brahim, CEO of One Biosciences, said in a statement.
"The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market."
MARKET SNAPSHOP
In 2024, Gustave Roussy, a European cancer research hospital, partnered with One Biosciences on a research project focused on bladder cancer, aiming to tailor therapeutic strategies to patients with this disease.
Gustave Roussy provided One Biosciences with anonymized data from 36 patients, offering valuable sources of information. In turn, One Biosciences utilized its discovery engine to gain a deeper understanding of the mechanisms of resistance to immunotherapy identified in certain patients.
In 2023, One Biosciences partnered with Assistance Publique-Hôpitaux de Paris (AP-HP), a consortium comprising nearly all hospitals in the greater Paris region, to conduct a research project on kidney disease.
Kidney disease is a condition characterized by a gradual loss of kidney function over time. It has no viable therapeutic option, and transplantation is often the only alternative, despite frequent relapses.
As part of the research partnership, One Biosciences accessed anonymized patient samples and clinical data, from four of AP-HP's hospitals (Hôpital Tenon, Hôpital Necker, Hôpital Kremlin-Bicêtre and Hôpitaux Universitaires Henri-Mondor).
The company then leveraged the data to identify new therapeutic targets for developing precision medicines and biomarkers to predict disease relapse via its discovery platform.
